
J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study
Betsy Goodfellow | May 21, 2024 | News story | Medical Communications | Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis
Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) as a treatment for patients with moderately to severely active ulcerative colitis (UC).
The trial demonstrated that 50% of those subcutaneously (SC) treated with 200mg Tremfya every four weeks and 45.2% of those treated with SC Tremfya 100mg every eight weeks achieved the primary endpoint of clinical remission at 44 weeks of treatment, compared to 18.9% in the placebo group.
Of these patients in clinical remission, 67% and 71%, respectively, were also in endoscopic remission at the 44 week mark, which indicates that they had a normal appearance of intestinal mucosa.
Both treatment groups also met all nine secondary endpoints.
David Lee MD PhD, global therapeutic area head of Immunology at J&J, commented: “The phase 3 QUASAR Maintenance Study continues to demonstrate the promise of Tremfya to unlock potential treatment options for patients living with UC who continue to experience debilitating symptoms despite the availability of treatments today. These findings underscore our commitment to elevate the standard of care in UC and strengthen our resolve to advance inflammatory bowel disease science.”
Betsy Goodfellow
Related Content

SMC accepts atogepant for acute migraine treatment in Scotland
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the …

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …






